Cortagen (Ala-Glu-Asp-Pro, cortex bioregulator)
Khavinson short peptide positioned as a cerebral cortex / brain-tissue bioregulator.
At a glance
What it is: Khavinson short peptide positioned as a cerebral cortex / brain-tissue bioregulator..
Primary research applications:
- Cortical-tissue support research (Khavinson framework)
- Brain-aging and recovery contexts in originating tradition
Editorial summary: Cortagen is the cerebral cortex entry in the Khavinson short-peptide framework — a tetrapeptide (Ala-Glu-Asp-Pro) positioned for cortical recovery and aging support. Same lineage-concentrated evidence pattern.
- Class / structure
- Tetrapeptide (Ala-Glu-Asp-Pro) — Khavinson cytogen
- Half-life
- Very short systemic half-life
- First described
- Khavinson group, post-2000
- Regulatory status
- Sold as a supplement; not FDA-approved
What is Cortagen?
Cortagen is a tetrapeptide bioregulator positioned within the Khavinson framework as supporting cerebral cortex function.
Discovery and development
Cortagen is one of the brain-targeted entries in the Khavinson short-peptide framework, alongside Pinealon. Where Pinealon is positioned for general cognitive and circadian function, Cortagen is positioned more specifically for cerebral cortex tissue and post-injury recovery contexts.
Mechanism of action
Within the Khavinson framework, Cortagen is proposed to reach the cell nucleus in cortical tissue and modulate gene expression in a tissue-selective way. Independent Western mechanistic validation is limited.[1]
Pharmacokinetics
Very short plasma half-life consistent with the Khavinson short-peptide family.
What the research shows
The peer-reviewed literature on Cortagen is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Supports cortical recovery and function as a bioregulator | Khavinson framework hypothesis | Uncertain |
| Has Western-grade clinical efficacy evidence | Limited | Uncertain |
Reported user experiences
How the research describes administration
Oral capsules in cyclic regimens within the Khavinson product line.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Cortagen is the cortical-tissue arm of the Khavinson framework. It sits in the same evidence position as the rest of the family — interesting concept, real research lineage, limited Western validation. For users exploring this category, Pinealon and Cortagen together represent the brain-targeted bioregulators in the framework.
Frequently asked questions
How does Cortagen differ from Pinealon?
Both are brain-targeted Khavinson short peptides. Pinealon is positioned more broadly for cognitive and circadian function; Cortagen is positioned more specifically for cerebral cortex tissue and post-injury recovery contexts.
References
- Khavinson VK. Peptides and ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. https://pubmed.ncbi.nlm.nih.gov/12422308/
- Khavinson VK, Linkova NS. Peptide bioregulators: a new class of geroprotectors. Adv Gerontol. 2020;10:34-45. https://pubmed.ncbi.nlm.nih.gov/?term=khavinson+cortagen